Phase 3 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a slow-growing (Grade 1 or 2) neuroendocrine tumour originating in the gut or pancreas that cannot be removed by surgery and has spread, and you are reasonably well enough to carry out daily activities (confirm with trial site)
- Your tumour has been growing after receiving 2 to 4 rounds of a specific type of radiation treatment called lutetium-177 (Lu-177), your disease was controlled for at least 6 months after that treatment, and scans show your tumour is visible and responds to a special type of imaging called SSTR-PET
- Your kidneys are working well enough, based on a blood test measuring kidney filtration rate
- Your blood counts are at acceptable levels — including red blood cells, white blood cells, and platelets
- Your liver protein (bilirubin) levels are not too high, based on a blood test
- Your blood protein (albumin) level is adequate, or your blood clotting is within a normal range
Who may not be able to join:
- You have previously had a type of radiation treatment delivered directly to the liver (radioembolization)
- You have significant heart problems, such as moderate-to-severe heart failure, reduced heart pumping ability, or an abnormal heart rhythm reading on an ECG
- You have high blood pressure that remains uncontrolled even while taking at least 3 blood pressure medications, one of which is a water tablet (diuretic)
- You have poorly controlled diabetes, shown by a blood sugar level test (HbA1c) of 8% or higher
- You have previously had a type of targeted radiation therapy other than Lu-177 (confirm with trial site)
- You need to take high-dose steroid tablets or injections, or you cannot stop taking them during the trial (steroid inhalers or creams are generally acceptable)
- You have a history of severe liver scarring (cirrhosis) or have had a liver transplant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ye Yuan, MD, RayzeBio Sr. Medical Director
Phone: +1 619 657 0057
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase 1b: RP3D; Phase 3: PFS as determined by BICR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.